Markets

Cytokinetics (CYTK) Jumps: Stock Adds 6.8% in Session - Tale of the Tape

Cytokinetics ( CYTK ) was a big mover last session, as its shares rose almost 7% on the day. The upside was driven by the start of Cytokinetics' Phase 3 clinical trial of tirasemtiv in patients with ALS (amyotrophic lateral sclerosis). This also led to far more shares changing hands than in a normal session. Yesterday's rally breaks the recent trend for the company since Jul 1, as the stock is now trading above the volatile price range of $6.01 to $6.52 in the past one-month time frame.

Over the last 30 days, the company has not seen any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cytokinetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is AMAG Pharmaceuticals, Inc. ( AMAG ) with a Zacks Rank #1 (Strong Buy).

Is CYTK going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

AMAG PHARMA INC (AMAG): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More